Publicaciones en colaboración con investigadores/as de Oslo University Hospital (23)

2024

  1. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

2023

  1. Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70

2022

  1. ADAMTSL3 knock-out mice develop cardiac dysfunction and dilatation with increased TGFβ signalling after pressure overload

    Communications Biology, Vol. 5, Núm. 1

  2. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  3. Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness

    Frontiers in Cell and Developmental Biology, Vol. 10

  4. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

2021

  1. Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma

    Frontiers in Cell and Developmental Biology, Vol. 9

  2. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  3. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer[Formula presented]

    European Urology, Vol. 80, Núm. 2, pp. 142-146

  4. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

    JAMA Network Open, Vol. 4, Núm. 12, pp. E2138550

  5. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

    Blood Cancer Journal, Vol. 11, Núm. 12

2020

  1. DNA methylation and body mass index from birth to adolescence: meta-analyses of epigenome-wide association studies

    Genome Medicine, Vol. 12, Núm. 1

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology

    SLAS Discovery, Vol. 24, Núm. 3, pp. 398-413

  3. Epigenome-wide meta-analysis of DNA methylation and childhood asthma

    Journal of Allergy and Clinical Immunology, Vol. 143, Núm. 6, pp. 2062-2074

  4. ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Nature Immunology

2017

  1. Maternal BMI at the start of pregnancy and offspring epigenome-wide DNA methylation: Findings from the pregnancy and childhood epigenetics (PACE) consortium

    Human Molecular Genetics, Vol. 26, Núm. 20, pp. 4067-4085

2016

  1. DNA Methylation in Newborns and Maternal Smoking in Pregnancy: Genome-wide Consortium Meta-analysis

    American Journal of Human Genetics, Vol. 98, Núm. 4, pp. 680-696

  2. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

2014

  1. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma

    International Journal of Cancer, Vol. 134, Núm. 1, pp. 102-113